David Thompson

I started at OCTO as a Clinical Trial Support Officer in 2015, with no previous experience in clinical trials; however, the position provided me with a great opportunity to start an exciting new career and develop my career skills within a motivating department. OCTO provided regular training sessions and support which enabled me to learn about all aspects of clinical trials, and after 3 years I was promoted to a Clinical Trial Administrator, and to Trial Manager in January 2020.

I currently work on:

IMP-MEL: A phase 1 first-in-human dose finding/randomised phase 2 study of IMM60 and pembrolizumab in advanced melanoma and NSCLC

CEeDD: A First-in-Human Clinical Investigation of Cavitation-Enhanced Drug Delivery to Solid Tumours by co-Administration of Sonosensitive Particles and Application of Extracorporeal Ultrasound in Patients with Colorectal Metastases to the Liver

I have previously worked on:

AspECT: A Phase III, randomised study of aspirin and esomeprazole chemoprevention in Barrett's metaplasia.

CAMELLIA: A Phase I dose escalation trial of the Humanized Anti-CD47 Monoclonal Antibody Hu5F9-G4 in Haematological Malignancies

NuTIDE:301: A two-part, Phase 1 open-label dose escalation and expansion study to assess safety, pharmacokinetics and clinical activity of NUC-3373, a nucleotide analogue, in participants with advanced solid tumours.